Mimedx (MDXG) Receivables (2010 - 2026)

Mimedx (MDXG) has 17 years of Receivables data on file, last reported at $55.6 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 16.01% year-over-year to $55.6 million; the trailing twelve-month figure through Mar 2026 stood at $55.6 million (down 16.01% YoY), and the FY2025 full-year result was $75.7 million, up 35.61% from the prior year.
• Receivables declined to $55.6 million in Q1 2026, from $75.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $78.2 million in Q3 2025 to a low of $37.7 million in Q2 2022.
• A 5-year average of $55.5 million and a median of $55.6 million in 2026 frame the typical range for Receivables.
• Across the five-year window, Receivables soared 44.71% in 2025 and slipped 16.01% in 2026, its largest moves.
• Tracing MDXG's Receivables over 5 years: stood at $43.1 million in 2022, then jumped by 32.33% to $57.0 million in 2023, then decreased by 2.08% to $55.8 million in 2024, then surged by 35.61% to $75.7 million in 2025, then dropped by 26.6% to $55.6 million in 2026.
• Business Quant data shows MDXG's Receivables at $55.6 million in Q1 2026, $75.7 million in Q4 2025, and $78.2 million in Q3 2025.